| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 34.95B | 34.80B | 35.42B | 34.09B | 31.29B | 29.83B |
| Gross Profit | 10.99B | 10.97B | 11.17B | 10.12B | 9.60B | 9.45B |
| EBITDA | 2.90B | 2.89B | 3.07B | 2.38B | 2.08B | 1.91B |
| Net Income | 1.23B | 1.29B | 1.42B | 988.73M | 823.62M | 738.16M |
Balance Sheet | ||||||
| Total Assets | 33.07B | 33.64B | 33.66B | 31.36B | 30.27B | 29.53B |
| Cash, Cash Equivalents and Short-Term Investments | 8.89B | 9.50B | 8.99B | 8.54B | 8.33B | 7.88B |
| Total Debt | 3.34B | 3.84B | 3.83B | 3.61B | 3.60B | 3.81B |
| Total Liabilities | 12.73B | 13.25B | 14.18B | 13.03B | 12.71B | 12.61B |
| Stockholders Equity | 18.27B | 18.30B | 17.50B | 16.48B | 15.83B | 15.24B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 1.47B | 1.37B | 639.73M | 948.76M | 623.27M |
| Operating Cash Flow | 0.00 | 2.23B | 2.41B | 1.11B | 1.78B | 1.21B |
| Investing Cash Flow | 0.00 | -993.79M | -1.46B | -443.35M | -684.06M | -568.92M |
| Financing Cash Flow | 0.00 | -730.63M | -492.73M | -454.03M | -630.46M | -509.30M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | ¥16.25B | 12.89 | ― | 3.89% | -3.00% | -29.83% | |
79 Outperform | ¥62.93B | 14.82 | ― | 2.88% | 3.42% | 13.37% | |
78 Outperform | ¥43.82B | 8.53 | ― | 3.53% | -3.45% | 30.52% | |
74 Outperform | ¥233.68B | 15.32 | ― | 4.09% | 1.69% | 0.94% | |
69 Neutral | ¥2.59T | 22.67 | ― | 1.11% | 2.35% | 0.43% | |
66 Neutral | ¥28.20B | 11.91 | ― | 3.53% | 6.99% | -0.30% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% |
Toho Acetylene reported consolidated net sales of ¥25.0 billion for the nine months ended December 31, 2025, a slight 0.8% decline year on year, with operating profit down 4.8% to ¥1.23 billion and profit attributable to owners of parent down 3.8% to ¥830 million.
Despite the modest profit decline, the company’s financial position strengthened marginally, with total assets rising to ¥33.9 billion and the equity ratio improving to 55.1%, while it kept its full-year forecast largely flat, projecting only slight sales growth and lower profits, and maintained its dividend outlook, signaling stable but subdued earnings momentum for stakeholders.
The most recent analyst rating on (JP:4093) stock is a Buy with a Yen388.00 price target. To see the full list of analyst forecasts on Toho Acetylene Co., Ltd. stock, see the JP:4093 Stock Forecast page.
Toho Acetylene Co., Ltd. has received approval from the Tokyo Stock Exchange to change its market segment listing from the Prime Market to the Standard Market, effective December 24, 2025. This strategic move aligns with the company’s focus on maintaining sufficient liquidity and governance levels while continuing to pursue growth and enhance corporate value. The company remains committed to improving its corporate governance and investor relations to meet shareholder expectations.
The most recent analyst rating on (JP:4093) stock is a Buy with a Yen401.00 price target. To see the full list of analyst forecasts on Toho Acetylene Co., Ltd. stock, see the JP:4093 Stock Forecast page.